Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases

Flavio Caprioli, Roberta Caruso, Massimiliano Sarra, Francesco Pallone, Giovanni Monteleone

Research output: Contribution to journalArticlepeer-review


Gut inflammation occurring in patients with inflammatory bowel diseases (IBD) is associated with an excessive immune response that is directed against constituents of the normal bacterial flora and results in the production of large amounts of inflammatory cytokines. Anti-cytokine compounds, such as the neutralizing TNF antibodies, have been employed with clinical success in patients with IBD. However, nearly half of IBD patients are refractory to such treatments, response can wane with time, and anti-TNF treatment can associate with severe side effects and/or development/exacerbation of extra-intestinal immune-mediated pathologies. These observations, and the demonstration that, in IBD, the pathological process is also characterized by defects in the production and/or activity of counter-regulatory cytokines, have boosted further studies aimed at delineating novel strategies to combat the IBD-associated tissue-damaging immune response.

Original languageEnglish
Pages (from-to)820-828
Number of pages9
JournalBritish Journal of Pharmacology
Issue number4
Publication statusPublished - Feb 2012


  • anti-IL-12
  • anti-IL-6R
  • anti-TNF
  • Crohn's disease
  • cytokines
  • IBD
  • ulcerative colitis

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases'. Together they form a unique fingerprint.

Cite this